JP2010500293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500293A5 JP2010500293A5 JP2009523120A JP2009523120A JP2010500293A5 JP 2010500293 A5 JP2010500293 A5 JP 2010500293A5 JP 2009523120 A JP2009523120 A JP 2009523120A JP 2009523120 A JP2009523120 A JP 2009523120A JP 2010500293 A5 JP2010500293 A5 JP 2010500293A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 101150109738 Ptger4 gene Proteins 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 0 CC(NS(*)(=O)=O)=O Chemical compound CC(NS(*)(=O)=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83725206P | 2006-08-11 | 2006-08-11 | |
| US60/837,252 | 2006-08-11 | ||
| PCT/CA2007/001404 WO2008017164A1 (en) | 2006-08-11 | 2007-08-10 | Thiophenecarboxamide derivatives as ep4 receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500293A JP2010500293A (ja) | 2010-01-07 |
| JP2010500293A5 true JP2010500293A5 (enExample) | 2010-09-16 |
| JP5259592B2 JP5259592B2 (ja) | 2013-08-07 |
Family
ID=39032586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523120A Expired - Fee Related JP5259592B2 (ja) | 2006-08-11 | 2007-08-10 | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8969394B2 (enExample) |
| EP (1) | EP2054401B1 (enExample) |
| JP (1) | JP5259592B2 (enExample) |
| CN (1) | CN101541778B (enExample) |
| AU (1) | AU2007283404B2 (enExample) |
| CA (1) | CA2660133C (enExample) |
| ES (1) | ES2421453T3 (enExample) |
| WO (1) | WO2008017164A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110028463A1 (en) * | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| CA2694347A1 (en) * | 2007-08-09 | 2009-02-12 | Merck Sharp & Dohme Corp. | Process for making thiophene carboxamide derivative |
| SI2565191T1 (sl) * | 2008-05-14 | 2014-12-31 | Astellas Pharma Inc. | Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije |
| EP2320906B1 (en) * | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| JP2013508282A (ja) | 2009-10-14 | 2013-03-07 | ジェンムス ファーマ インコーポレイティド | ウイルス感染のための併用療法処置 |
| MX341482B (es) * | 2010-02-22 | 2016-08-22 | Raqualia Pharma Inc | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. |
| PH12013500467A1 (en) | 2010-09-21 | 2013-04-29 | Eisai R&D Man Co Ltd | Pharmaceutical composition |
| CA2820109C (en) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| KR102556734B1 (ko) | 2013-03-19 | 2023-07-18 | 에스크엣 인크. | 연골질환 치료에서의 ep4 수용체 길항제의 용도 |
| PT3009426T (pt) | 2013-06-12 | 2018-06-08 | Kaken Pharma Co Ltd | Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativo |
| EP3492106B1 (en) | 2013-08-09 | 2021-02-17 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| US20170182003A1 (en) * | 2014-05-23 | 2017-06-29 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of cancer |
| US9926262B2 (en) * | 2014-06-06 | 2018-03-27 | Allergan, Inc. | EP4 agonists as therapeutic compounds |
| CN105037186A (zh) * | 2015-06-17 | 2015-11-11 | 苏州敬业医药化工有限公司 | 一种氨甲苯酸的制备方法 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018162562A1 (en) | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| MX388257B (es) | 2017-05-18 | 2025-03-19 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2. |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| US20200069686A1 (en) | 2017-05-18 | 2020-03-05 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| US10202415B1 (en) | 2017-10-19 | 2019-02-12 | King Saud University | Method of synthesizing of 3-oxolupenal nanoparticles |
| EP3972599B1 (en) | 2019-05-21 | 2025-10-22 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
| CN112552200B (zh) * | 2019-09-10 | 2024-03-12 | 烟台药物研究所 | 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法 |
| US20240002388A1 (en) * | 2020-08-18 | 2024-01-04 | Hutchison Medipharma Limited | Pyrimidinone compounds and uses thereof |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| EP0752421B1 (en) | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
| BR0116850A (pt) * | 2001-01-31 | 2004-02-25 | Pfizer Prod Inc | Derivados de amida de ácido tiazolil-, oxazolil-, pirrolil- e imidazolil- úteis como inibidores de isoenzimas de pde4 |
| WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| RS20060143A (sr) * | 2003-09-03 | 2008-06-05 | Pfizer Inc., | Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2 |
| GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| CA2563356A1 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
| JP4054368B2 (ja) * | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | 置換メチルアリール又はヘテロアリールアミド化合物 |
| CN1950334A (zh) * | 2004-05-04 | 2007-04-18 | 辉瑞有限公司 | 邻位取代的芳基或杂芳基酰胺化合物 |
| WO2005116010A1 (en) * | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
-
2007
- 2007-08-10 CA CA2660133A patent/CA2660133C/en not_active Expired - Fee Related
- 2007-08-10 CN CN200780037574.4A patent/CN101541778B/zh not_active Expired - Fee Related
- 2007-08-10 ES ES07815782T patent/ES2421453T3/es active Active
- 2007-08-10 AU AU2007283404A patent/AU2007283404B2/en not_active Ceased
- 2007-08-10 EP EP07815782.3A patent/EP2054401B1/en active Active
- 2007-08-10 JP JP2009523120A patent/JP5259592B2/ja not_active Expired - Fee Related
- 2007-08-10 US US12/309,941 patent/US8969394B2/en active Active
- 2007-08-10 WO PCT/CA2007/001404 patent/WO2008017164A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500293A5 (enExample) | ||
| JP2008539267A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2013056886A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| JP2009507909A5 (enExample) | ||
| JP2010522710A5 (enExample) | ||
| JP2009524676A5 (enExample) | ||
| EA022527B1 (ru) | 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ | |
| JP2008513496A5 (enExample) | ||
| JP2010523476A5 (enExample) | ||
| JP2013512277A5 (enExample) | ||
| JP2012502927A5 (enExample) | ||
| JP2011513410A5 (enExample) | ||
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP2013511556A5 (enExample) | ||
| JP2011523952A5 (enExample) | ||
| JP2008539268A5 (enExample) | ||
| JP2007522142A5 (enExample) | ||
| JP2013514980A5 (enExample) | ||
| JP2013521301A5 (enExample) |